高危原发性血小板增多症和真性红细胞增多症患者接受羟基脲或聚乙二醇干扰素α-2a治疗的症状负担与生活质量:MPN-RC 111和112试验的事后分析
对MPN-RC 111(单臂2期,17家中心)和MPN-RC 112(随机3期,25家中心)两项试验的事后分析,纳入114例和166例高危原发性血小板增多症或真性红细胞增多症患者,评估症状负担随细胞减灭治疗的变化。12个月时,完全及部分缓解者中报告症状负担临床显著改善的比例高于无缓解者(44/191[22%] vs 4/76[5%],Fisher精确检验p=0.0003);基线高症状负担者3至12个月症状改善,低负担者则加重。
要点
- 12个月时完全及部分缓解者症状临床显著改善比例高于无缓解者(22% vs 5%,p=0.0003)。
- 基线高症状负担(总分≥20)者3至12个月症状改善,聚乙二醇干扰素α-2a组平均变化-10.2,羟基脲组-6.8。
- 基线低症状负担(总分<20)者3至12个月症状加重,聚乙二醇干扰素α-2a组平均变化3.2,羟基脲组3.4。
核心结论
- 从患者角度测量症状负担对理解疗效和耐受性至关重要,结果可帮助制定原发性血小板增多症和真性红细胞增多症的治疗决策,包括治疗时机和目标。
研究设计与样本
- MPN-RC 111为单臂、开放标签、2期多中心试验,在意大利和美国17家医院及癌症中心开展,纳入对羟基脲耐药或不耐受患者(NCT01259817)。
- MPN-RC 112为随机、开放标签、3期多中心试验,在法国、德国、以色列、意大利、英国和美国25家医院及癌症中心开展,比较聚乙二醇干扰素α-2a与羟基脲(NCT01258856)。
- 本分析纳入MPN-RC 111的114例患者(64例[56%]原发性血小板增多症,50例[44%]真性红细胞增多症;56例[49%]女性;110例中100例[91%]为白人)和MPN-RC 112的166例患者(79例[48%]原发性血小板增多症,87例[52%]真性红细胞增多症;68例[41%]女性;156例中145例[93%]为白人)。
主要发现
- MPN-RC 111于2012年2月15日至2015年12月23日入组135例,MPN-RC 112于2011年9月24日至2016年6月30日入组168例。
- 12个月时症状负担临床显著改善(MPN-SAF总症状评分较基线改善≥50%):MPN-RC 111聚乙二醇干扰素α-2a组完全缓解者38例中12例(32%)、部分缓解者35例中7例(20%)。
- MPN-RC 112聚乙二醇干扰素α-2a组完全缓解者27例中5例(19%)、部分缓解者34例中6例(18%);羟基脲组完全缓解者30例中8例(27%)、部分缓解者27例中6例(22%)。
- 完全及部分缓解者报告临床显著改善的比例高于无缓解者(191例中44例[22%] vs 76例中4例[5%],Fisher精确检验p=0.0003)。
- 基线高症状负担者3至12个月症状改善:聚乙二醇干扰素α-2a组平均总症状评分变化-10.2(95%CI -13.2至-7.2),羟基脲组-6.8(95%CI -11.2至-2.4);基线低症状负担者症状加重:聚乙二醇干扰素α-2a组3.2(95%CI 0.9至5.4),羟基脲组3.4(95%CI 0.6至6.2)。
关键数值与推荐
- 症状负担临床显著改善定义为基线总症状评分大于0的患者12个月时MPN-SAF总症状评分较基线改善≥50%。
- 基线症状负担按MPN-SAF总症状评分分为高负担(≥20)与低负担(<20)。
- 主要终点为治疗开始后12个月内通过MPN-SAF和欧洲癌症研究与治疗组织核心生活质量问卷评估的症状负担。
临床怎么用
- 原文结论认为结果可帮助制定原发性血小板增多症和真性红细胞增多症的治疗决策,包括治疗时机和目标,作者指出从患者角度测量症状负担对理解疗效和耐受性至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with essential thrombocythaemia or polycythaemia vera have several symptoms that can worsen their quality of life. We aimed to assess how symptom burden changes over time with cytoreductive therapy. METHODS: We performed a post-hoc analysis of data from MPN-RC 111-a single-arm, open-label, phase 2, multicentre trial at 17 hospitals and cancer centres in Italy and the USA, evaluating the clinical-haematological response to pegylated interferon alfa-2a in patients who were resistant or intolerant to hydroxyurea (NCT01259817)-and MPN-RC 112-a randomised, open-label, phase 3, multicentre trial at 25 hospitals and cancer centres in France, Germany, Israel, Italy, the UK, and the USA, comparing the clinical-haematological response to pegylated interferon alfa-2a versus hydroxyurea in therapy-naive patients with either high-risk essential thrombocythaemia or polycythaemia vera (NCT01258856). Patients completed the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and the European Organisation for the Research and Treatment of Cancer Core Quality of Life Questionnaire through 12 months after initiation of treatment as secondary endpoints. In this post-hoc analysis, we examined the association of symptom burden with the clinical-haematological response at 12 months and the effect of baseline symptom burden (ie, high burden [total symptom score ≥20] vs low burden [total symptom score <20]) on subsequent changes in symptoms, estimated via mixed models. A clinically significant improvement in symptom burden was defined as 50% or greater improvement in the MPN-SAF total symptom score from baseline to 12 months in patients with a total symptom score greater than zero at baseline. FINDINGS: 135 patients were enrolled in MPN-RC 111 between Feb 15, 2012, and Dec 23, 2015, and 168 were enrolled in MPN-RC 112 between Sept 24, 2011, and June 30, 2016. For this analysis, we included data from 114 patients from MPN-RC 111 (64 [56%] with essential thrombocythaemia and 50 [44%] with polycythaemia vera; 56 [49%] were female, and 100 [91%] of 110 were white) and 166 patients from MPN-RC 112 (79 [48%] with essential thrombocythaemia and 87 [52%] with polycythaemia vera; 68 [41%] were female, and 145 [93%] of 156 were white). At 12 months, a clinically significant improvement in symptom burden was reported by 12 (32%) of 38 complete responders and seven (20%) of 35 partial responders treated with pegylated interferon alfa-2a in MPN-RC 111; five (19%) of 27 complete responders and six (18%) of 34 partial responders treated with pegylated interferon alfa-2a in MPN-112; and eight (27%) of 30 complete responders and six (22%) of 27 partial responders treated with hydroxyurea in MPN-112. More complete and partial responders reported a clinically significant improvement than did non-responders (44 [22%] of 191 complete and partial responders vs four [5%] of 76 non-responders; Fisher's exact p=0·0003). Symptom burden improved between 3 and 12 months in patients with high baseline symptom burden, both those treated with pegylated interferon alfa-2a (mean total symptom score change -10·2, 95% CI -13·2 to -7·2) and those treated with hydroxyurea (-6·8, -11·2 to -2·4). However, symptom burden worsened between 3 and 12 months in patients with low baseline symptom burden (patients treated with pegylated interferon alfa-2a: mean total symptom score change 3·2, 95% CI 0·9 to 5·4; patients treated with hydroxyurea: 3·4, 0·6 to 6·2). INTERPRETATION: Results can inform treatment decisions, including treatment timing and goals in managing essential thrombocythaemia and polycythaemia vera, because measuring symptom burden from the patient perspective is crucial to understanding treatment efficacy and tolerability. FUNDING: US National Cancer Institute of the National Institutes of Health, and Roche Genentech.
引用
- Mazza GL, Mead-Harvey C, Mascarenhas J, et al. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Lancet Haematol. 2022. PMID: 34971581. doi:10.1016/S2352-3026(21)00343-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。